EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies

Robert Klamroth iD, Annette von Drygalski, Cedric Hermans iD, Young-Shil Park iD, Anthony K C Chan iD, Alphan Kupesiz iD, María Teresa Alvarez-Román iD, Lynn Malec iD, Elena Santagostino, Graham Neill, Linda Bystrická iD, Jennifer Dumont und 3 weitere

Haemophilia · 2025-05 · 31 (3) · 391-400

DOI: 10.1111/hae.70017 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Haemophilia, online erschienen am 18.03.2025. Verfasst von Robert Klamroth und 14 weiteren Autor:innen. Beteiligte Einrichtung: Vivantes Klinikum, Friedrichshain, Berlin, and Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Facul…. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Perioperative Care. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi (Cambridge, MA), Sobi (Stockholm, Sweden).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Phase 3 studies, XTEND‐1 (NCT04161495) and XTEND‐Kids (NCT04759131), showed once‐weekly efanesoctocog alfa provided high‐sustained factor VIII (FVIII) activity levels that translated into highly effective bleed prevention in patients with severe haemophilia A.

Aim

This analysis evaluated the efficacy and safety of efanesoctocog alfa for perioperative management during XTEND‐1 and XTEND‐Kids.

Methods

Patients undergoing major or minor surgery were to receive a single preoperative 50 IU/kg dose, with additional 30 or 50 IU/kg doses every 2–3 days as needed following major surgery. Outcomes assessed included FVIII activity levels, number and dose of efanesoctocog alfa injections, surgeon's/investigator's assessment of haemostatic response, total factor consumption, estimated blood loss, number and type of blood transfusions, and safety.

Results

In XTEND‐1, 11 adults/adolescents underwent 12 evaluable major surgeries (6 orthopaedic). Eleven surgeries had one preoperative dose (median [range]: 49.9 [13–52] IU/kg); one had no preoperative dose. Median (range) total consumption from Day −1 to 14 was 163.3 (45–361) IU/kg. In XTEND‐Kids, two children underwent major surgery with a single preoperative loading dose (60.4 and 61.9 IU/kg). Across trials, 15 adults/adolescents underwent 18 minor surgeries and 8 children underwent 9 minor surgeries, with a single preoperative dose or no preoperative dose (5 surgeries in adults/adolescents). Haemostatic response was rated excellent for all surgeries. No surgeries required blood transfusion. No safety concerns or inhibitor development was reported.

Conclusion

Efanesoctocog alfa provided highly effective perioperative protection in patients with severe haemophilia A. Trial Registration : XTEND‐1: NCT04161495 https://clinicaltrials.gov/study/NCT04161495 ; XTEND‐Kids: NCT04759131 https://clinicaltrials.gov/study/NCT04759131

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIPerioperative CareHumansAdultAdolescentMaleYoung AdultChildMiddle AgedBlood Loss, SurgicalFemaleTreatment Outcome

Stichwörter der Autor:innen

BIVV001adultschildrenhaematologyhaemophiliahaemostasissurgical procedures, operative

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Vivantes Klinikum, Friedrichshain, Berlin, and Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany.
  • Department of Medicine, Division of Hematology/Oncology, University of California San Diego, San Diego, California, USA.
  • Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
  • Department of Pediatrics, Division of Hematology/Oncology, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
  • McMaster Children's Hospital, McMaster University, Hamilton, Canada.
  • Akdeniz University, Antalya, Turkey.

ORCID-Profile: Robert Klamroth, Cedric Hermans, Young-Shil Park, Anthony K C Chan, Alphan Kupesiz, María Teresa Alvarez-Román, Lynn Malec, Linda Bystrická

Förderung

  • Sanofi (Cambridge, MA)
  • Sobi (Stockholm, Sweden)

Zitieren

APA

Klamroth, R., von Drygalski, A., Hermans, C., Park, Y. S., Chan, A. K. C., Kupesiz, A., Alvarez-Román, M. T., Malec, L., Santagostino, E., Neill, G., Bystrická, L., Dumont, J., Abad-Franch, L., Fetita, L. S., & Khoo, L. (2025). Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies. Haemophilia, 31(3), 391-400. https://doi.org/10.1111/hae.70017

Vancouver

Klamroth R, von Drygalski A, Hermans C, Park YS, Chan AKC, Kupesiz A, et al. Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies. Haemophilia. 2025;31(3):391-400. doi:10.1111/hae.70017

BibTeX
@article{Klamroth2025,
  author = {Klamroth, Robert and von Drygalski, Annette and Hermans, Cedric and Park, Young-Shil and Chan, Anthony K C and Kupesiz, Alphan and Alvarez-Román, María Teresa and Malec, Lynn and Santagostino, Elena and Neill, Graham and Bystrická, Linda and Dumont, Jennifer and Abad-Franch, Lydia and Fetita, Lila-Sabrina and Khoo, Liane},
  title = {Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies},
  journal = {Haemophilia},
  year = {2025},
  volume = {31},
  number = {3},
  pages = {391--400},
  doi = {10.1111/hae.70017}
}
Kostenlos starten →